Your browser doesn't support javascript.
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
Meng, Fanping; Xu, Ruonan; Wang, Siyu; Xu, Zhe; Zhang, Chao; Li, Yuanyuan; Yang, Tao; Shi, Lei; Fu, Junliang; Jiang, Tianjun; Huang, Lei; Zhao, Peng; Yuan, Xin; Fan, Xing; Zhang, Ji-Yuan; Song, Jinwen; Zhang, Dawei; Jiao, Yanmei; Liu, Limin; Zhou, Chunbao; Maeurer, Markus; Zumla, Alimuddin; Shi, Ming; Wang, Fu-Sheng.
  • Meng F; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Xu R; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Wang S; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Xu Z; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Zhang C; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Li Y; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Yang T; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Shi L; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Fu J; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Jiang T; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Huang L; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Zhao P; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Yuan X; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Fan X; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Zhang JY; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Song J; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Zhang D; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Jiao Y; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Liu L; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Zhou C; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
  • Maeurer M; Immunotherapy Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal.
  • Zumla A; I Med Clinic, University of Mainz, Mainz, Germany.
  • Shi M; Department of Infection, Division of Infection and Immunity, University College London, London, UK.
  • Wang FS; National Institute for Health Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
Signal Transduct Target Ther ; 5(1): 172, 2020 08 27.
Article in English | MEDLINE | ID: covidwho-733534
Semantic information from SemMedBD (by NLM)
1. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
2. Lung LOCATION_OF Tissue damage
Subject
Lung
Predicate
LOCATION_OF
Object
Tissue damage
3. Functional Disability PROCESS_OF Survivors
Subject
Functional Disability
Predicate
PROCESS_OF
Object
Survivors
4. Human mesenchymal stem cell TREATS Patients
Subject
Human mesenchymal stem cell
Predicate
TREATS
Object
Patients
5. COVID-19 PROCESS_OF hospitalized patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
hospitalized patients
6. Hypoxia PROCESS_OF Patients
Subject
Hypoxia
Predicate
PROCESS_OF
Object
Patients
7. Fever PROCESS_OF Patients
Subject
Fever
Predicate
PROCESS_OF
Object
Patients
8. Flushing PROCESS_OF Patients
Subject
Flushing
Predicate
PROCESS_OF
Object
Patients
9. Mechanical ventilation TREATS Patients
Subject
Mechanical ventilation
Predicate
TREATS
Object
Patients
10. Intravenous infusion procedures TREATS Patients
Subject
Intravenous infusion procedures
Predicate
TREATS
Object
Patients
11. Cessation of life PROCESS_OF Patients
Subject
Cessation of life
Predicate
PROCESS_OF
Object
Patients
12. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
13. Lung LOCATION_OF Tissue damage
Subject
Lung
Predicate
LOCATION_OF
Object
Tissue damage
14. Functional Disability PROCESS_OF Survivors
Subject
Functional Disability
Predicate
PROCESS_OF
Object
Survivors
15. Human mesenchymal stem cell TREATS Patients
Subject
Human mesenchymal stem cell
Predicate
TREATS
Object
Patients
16. COVID-19 PROCESS_OF hospitalized patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
hospitalized patients
17. Hypoxia PROCESS_OF Patients
Subject
Hypoxia
Predicate
PROCESS_OF
Object
Patients
18. Fever PROCESS_OF Patients
Subject
Fever
Predicate
PROCESS_OF
Object
Patients
19. Flushing PROCESS_OF Patients
Subject
Flushing
Predicate
PROCESS_OF
Object
Patients
20. Mechanical ventilation TREATS Patients
Subject
Mechanical ventilation
Predicate
TREATS
Object
Patients
21. Intravenous infusion procedures TREATS Patients
Subject
Intravenous infusion procedures
Predicate
TREATS
Object
Patients
22. Cessation of life PROCESS_OF Patients
Subject
Cessation of life
Predicate
PROCESS_OF
Object
Patients
ABSTRACT
No effective drug treatments are available for coronavirus disease 2019 (COVID-19). Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage, death, or long-term functional disability in survivors require clinical evaluation. We performed a parallel assigned controlled, non-randomized, phase 1 clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease. The study enrolled 18 hospitalized patients with COVID-19 (n = 9 for each group). The treatment group received three cycles of intravenous infusion of UC-MSCs (3 × 107 cells per infusion) on days 0, 3, and 6. Both groups received standard COVID-treatment regimens. Adverse events, duration of clinical symptoms, laboratory parameters, length of hospitalization, serial chest computed tomography (CT) images, the PaO2/FiO2 ratio, dynamics of cytokines, and IgG and IgM anti-SARS-CoV-2 antibodies were analyzed. No serious UC-MSCs infusion-associated adverse events were observed. Two patients receiving UC-MSCs developed transient facial flushing and fever, and one patient developed transient hypoxia at 12 h post UC-MSCs transfusion. Mechanical ventilation was required in one patient in the treatment group compared with four in the control group. All patients recovered and were discharged. Our data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated. Phase 2/3 randomized, controlled, double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC-MSCs to reduce deaths and improve long-term treatment outcomes in patients with serious COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Pneumonia, Viral / Hematopoietic Stem Cells / Coronavirus Infections / Cord Blood Stem Cell Transplantation / Mesenchymal Stem Cell Transplantation / Betacoronavirus / Antibodies, Viral Subject: Pneumonia, Viral / Hematopoietic Stem Cells / Coronavirus Infections / Cord Blood Stem Cell Transplantation / Mesenchymal Stem Cell Transplantation / Betacoronavirus / Antibodies, Viral Type of study: Controlled clinical trial / Observational study Language: English Journal: Signal Transduct Target Ther Clinical aspect: Prognosis / Therapy Year: 2020

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Pneumonia, Viral / Hematopoietic Stem Cells / Coronavirus Infections / Cord Blood Stem Cell Transplantation / Mesenchymal Stem Cell Transplantation / Betacoronavirus / Antibodies, Viral Subject: Pneumonia, Viral / Hematopoietic Stem Cells / Coronavirus Infections / Cord Blood Stem Cell Transplantation / Mesenchymal Stem Cell Transplantation / Betacoronavirus / Antibodies, Viral Type of study: Controlled clinical trial / Observational study Language: English Journal: Signal Transduct Target Ther Clinical aspect: Prognosis / Therapy Year: 2020
...